Who we work with

We provided BASF with a volume guarantee to reduce the price of at least 35 million dual-action Interceptor® G2 mosquito nets, a next-generation tool to tackle growing mosquito resistance to existing nets.

We provided Biovac with a $10 million loan to build an end-to-end vaccine manufacturing facility in Cape Town, boosting regional production and strengthening vaccine supply security in Africa.

We work with dsm-firmenich to support stable, affordable pricing and reliable supply of vitamin A, giving edible oil millers in low- and middle-income countries better visibility on their production costs.

We will provide Elekta with volume guarantees for radiotherapy machines placed in health facilities in Kenya and Tanzania, enabling the company to offer a pay-per use model that reduces upfront costs and improves price transparency.

We partnered with the Gates Foundation to provide a volume guarantee to BASF to accelerate access to their next-generation Interceptor® G2 mosquito nets.

Our agreement with Gavi and GSK supported continued production of antigen for the RTS,S malaria vaccine ahead of key policy decisions.

Our agreement with GSK and Gavi, the Vaccine Alliance supported continued production of antigen for the RTS,S malaria vaccine ahead of key policy decisions.

We provided a working capital facility to Hemex to help scale access to its portable Gazelle® sickle cell testing platform across India, Africa and the Middle East.

We provided a volume guarantee to Kenyan supplier Hewatele to increase the supply of affordable, locally produced medical oxygen, as part of the East Africa Programme on Oxygen Access.

We provided Hologic with a volume guarantee that enabled the company to offer an all-inclusive $12 ceiling price per patient test, making routine viral load testing on its Panther® platform more accessible.

We provided Macleods with a volume guarantee for its 3HP short-course TB preventive therapy, improving affordability and supply security in line with the goals of the IMPAACT4TB partnership.

We worked with the Open Society Foundations to provide Gavi with a risk-sharing facility, supporting the COVAX cost-sharing mechanism to get COVID-19 vaccines to lower-income countries.

Our volume guarantees helped SD Biosensor reduce the price of dual HIV and syphilis testing, and to maintain supply of G6PD testing devices and strips used to tackle P. vivax malaria.

We provided a volume guarantee to Kenyan supplier Synergy to increase the supply of affordable, locally produced medical oxygen, as part of the East Africa Programme on Oxygen Access.

Our guarantees have helped UNICEF respond to country demand for essential health products, including during the COVID-19 pandemic when many countries relied on UNICEF’s bulk purchasing power.

We provided Viatris with a volume guarantee that reduced the price of pretomanid, part of a WHO-recommended shorter treatment regimen for drug-resistant tuberculosis.

We provided Wondfo with a volume guarantee that cut the price of its WHO-prequalified HIV self-test to $1, accelerating access for more people at risk of HIV.

We were founded by British International Investment (BII). The UK’s development finance institution is our anchor investor with $170 million of paid-in capital through its Catalyst Strategies portfolio.

Coefficient Giving’s grant supports our work to explore market-shaping interventions that could speed the rollout of future adolescent and adult TB vaccines in high-burden countries.

The EIB’s Guarantee Agreement, worth up to €52 million, provides a counter-guarantee covering up to 30% of losses that MedAccess may incur on eligible volume guarantees, expanding our capacity to accelerate access to health products across Africa.

FCDO’s support allows us to do the detailed work to craft volume guarantee agreements for HIV, TB and malaria, in line with the goals of the Global Fund.

A grant from the Gates Foundation enabled us to explore opportunities to stabilise the market for micronutrients used in large-scale food fortification. It enabled us to craft an agreement aimed at improving access to vitamin A for food fortification.

Wellcome’s grant allows us to scope opportunities to use innovative finance and market shaping tools to increase access to products for mental health conditions in Africa.

We collaborate with the Access to Medicine Foundation, an independent research foundation that encourages healthcare companies to improve access to their products in low- and middle-income countries.

The EIB’s Guarantee Agreement, worth up to €52 million, provides a counter-guarantee covering up to 30% of losses that MedAccess may incur on eligible volume guarantees, expanding our capacity to accelerate access to health products across Africa.

We work with the Global Fund to make HIV, TB and malaria products more affordable, so that more people can be protected from these infectious diseases.

We work with Unitaid to combine our financial tools and expertise for health impact. Our partnership has helped improve access to next-generation mosquito nets, treatment for latent TB and locally-produced oxygen.

We work with CHAI’s market shaping and country teams to ensure our agreements achieve their intended impact and solve any issues in real time.

IVCC partnered with BASF to support the development of Interceptor® G2 mosquito nets. IVCC also leads the New Nets Project, which was funded by the Global Fund and Unitaid.

We work with PATH to accelerate access to SD Biosensor’s G6PD testing devices and strips, which help health workers give people with P. vivax malaria the most effective treatment.

We work with TB Alliance to accelerate the introduction and uptake of a WHO-recommended regimen for multidrug-resistant tuberculosis.